Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences (CRBU), a CRISPR genome-editing biopharmaceutical company, announced that CEO Rachel Haurwitz will participate in a fireside chat on October 4, 2021, at the Chardan Virtual 5th Annual Genetic Medicines Conference. Haurwitz will also be part of a panel discussion titled "Gene Editing: Next-Generation Technologies Worth Watching" on October 5, 2021. The live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event.
Caribou aims to advance genome-edited therapies using its proprietary chRDNA technology.
Caribou Biosciences (Nasdaq:CRBU) has published data in Molecular Cell outlining its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology, demonstrating enhanced genome editing specificity.
The study reveals that chRDNA guides outperform all-RNA guides in reducing off-target edits while achieving efficient genomic modifications, crucial for the development of CAR-T therapies targeting hematologic malignancies.
Initial clinical data from ongoing trials of their multiplex-edited candidate CB-010 is anticipated in 2022, signaling significant potential for therapeutic advancements.
Caribou Biosciences, Inc. (Nasdaq: CRBU) completed an upsized IPO, raising $349.6 million, alongside reporting Q2 2021 financial results. The company dosed its first patient in the ANTLER Phase 1 trial for CB-010 targeting relapsed B cell non-Hodgkin lymphoma. However, Caribou faced a substantial decrease in licensing revenue, down to $1.5 million from $8.5 million year-over-year. R&D expenses rose to $12.3 million, while G&A expenses increased to $5.1 million, contributing to a net loss of $14.3 million, a notable rise from the previous year's $1.9 million loss.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will join a panel at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, at 10:40 am ET. The panel, titled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” will focus on advances in cell therapies. A live and archived webcast will be available for 30 days on the company’s website. Caribou is committed to developing next-generation, genome-edited cell therapies using its proprietary technology.
Caribou Biosciences (Nasdaq: CRBU) has appointed Nancy Whiting, Pharm.D., to its board of directors. With over 17 years in biotechnology, Whiting has extensive experience in drug development, especially in oncology, which aligns with Caribou’s focus on advancing its cell therapy pipeline. Her previous role was as executive vice president at Seagen Inc., where she led late-stage clinical development. The company aims to leverage her expertise as it develops CRISPR-edited therapies for cancer treatment.
Caribou Biosciences, Inc. (Nasdaq: CRBU) has successfully closed its initial public offering of 19,000,000 shares at $16.00 each, raising approximately $304 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 2,850,000 shares. Shares began trading on the Nasdaq on July 23, 2021. BofA Securities, Citigroup, and SVB Leerink acted as joint book-running managers. The registration statements were effective on July 22, 2021, allowing the offering to proceed under SEC regulations.
Caribou Biosciences priced its upsized initial public offering (IPO) of 19,000,000 shares at $16.00 each, aiming for gross proceeds of $304 million. The shares will trade on Nasdaq under the symbol CRBU, beginning July 23, 2021, with the offering expected to close around July 27, 2021. Underwriters have a 30-day option to purchase an additional 2,850,000 shares. BofA Securities, Citigroup, and SVB Leerink are serving as joint book-running managers for the offering.